Sugi Predict

Sugi Predict / Compounds / SCHEMBL731550

SCHEMBL731550

SCHEMBL731550

N[C@H]1CCOC(=O)[C@@H](N)CCOC1=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.32
▸ BLM P54132 2/20 0.32
▸ LMNA P02545 2/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ GRIN2D O15399 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ PTGS1 P23219 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ GRIN1 Q05586 1/20 0.32
▸ GRIN2A Q12879 1/20 0.32
▸ GRIN2B Q13224 1/20 0.32
▸ GRIN2C Q14957 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ HIF1A Q16665 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Homoserine Lactone SCHEMBL79969 1.00 — —
Homoserine Lactone SCHEMBL79466 1.00 — —
Homoserine Lactone SCHEMBL79968 1.00 — —
Homoserine Lactone SCHEMBL1034274 0.97 — —
Homoserine Lactone SCHEMBL1147212 0.97 — —
Homoserine Lactone SCHEMBL787339 0.97 — —
Homoserine Lactone SCHEMBL1402931 0.97 — —
Homoserine Lactone SCHEMBL7217249 0.97 — —
Homoserine Lactone SCHEMBL1536657 0.97 — —
Homoserine Lactone SCHEMBL15227619 0.93 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104862352-B Microorganism producing O-phosphoserine and method for producing L-cysteine or derivative thereof from O-phosphoserine using the same CJ第一制糖株式会社 2021-10-26 — — CN claimed
US-10738091-B2 RHTB protein variants and the method of producing O-phosphoserine using the same CJ CHEILJEDANG CORPORATION (KR) 2020-08-11 — — US claimed
US-20190023749-A1 NOVEL RHTB PROTEIN VARIANTS AND THE METHOD OF PRODUCING O-PHOSPHOSERINE USING THE SAME CJ CHEILJEDANG CORPORATION (KR) 2019-01-24 — — US claimed
CN-105377878-B New RhtB protein variant and the method for generating O- phosphoserine using it CJ第制糖株式会社 2018-12-18 — — CN claimed
EP-2444481-B1 Microorganism producing O-phosphoserine and method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same CJ CHEILJEDANG CORP (KR) 2018-11-28 — — EP claimed
US-10125179-B2 RhtB protein variants and the method of producing O-phosphoserine using the same CJ CHEILJEDANG CORPORATION (KR) 2018-11-13 — — US claimed
EP-2994478-B1 NOVEL RHTB PROTEIN VARIANTS AND THE METHOD OF PRODUCING O-PHOSPHOSERINE USING THE SAME CJ CHEILJEDANG CORP (KR) 2018-02-28 — — EP claimed
US-20170342115-A1 NOVEL RHTB PROTEIN VARIANTS AND THE METHOD OF PRODUCING O-PHOSPHOSERINE USING THE SAME CJ CHEILJEDANG CORPORATION (KR) 2017-11-30 — — US claimed
US-9765124-B2 RhtB protein variants and the method of producing O-phosphoserine using the same CJ CHEILJEDANG CORPORATION (KR) 2017-09-19 — — US claimed
US-9689009-B2 Microorganism producing o-phosphoserine and method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same CJ CHEILJEDANG CORPORATION (KR) 2017-06-27 — — US claimed
EP-0925308-B1 COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN MICROLOGIX BIOTECH INC (CA) 2002-06-05 — — EP claimed
US-20020035061-A1 COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS BIOWEST THERAPEUTICS INC. (CA) 2002-03-21 — — US claimed
EP-1174439-A2 Compositions and methods for treating infections using analogues of indolicidin Micrologix Biotech, Inc. (CA) 2002-01-23 — — EP claimed
US-6180604-B1 Compositions and methods for treating infections using analogues of indolicidin MICROLOGIX BIOTECH INC. (CA) 2001-01-30 — — US claimed
JP-2001500477-A — — 2001-01-16 — — JP claimed
EP-0966481-A2 COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS Micrologix Biotech, Inc. (CA) 1999-12-29 — — EP claimed
EP-0925308-A2 COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN Micrologix Biotech, Inc. (CA) 1999-06-30 — — EP claimed
WO-1998040401-A2 COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS MICROLOGIX BIOTECH INC. (CA) 1998-09-17 — — WO claimed
WO-1998007745-A9 COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN — 1998-04-23 — — WO claimed
WO-1998007745-A2 COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN MICROLOGIX BIOTECH, INC. (CA) 1998-02-26 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035061-A1 COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS VIP, PEPD, PTMS TSHR 3173/4885BLM 1933/4885LMNA 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.